- Mersana Therapeutics ( NASDAQ: MRSN ) on Wednesday said the European Commission had granted an orphan drug designation to its antibody drug conjugate for the treatment of ovarian cancer.
- The designation was given to MRSN's upifitamab rilsodotin (UpRi) product.
- The European Medicines Agency's orphan designation is given to medicines developed for rare, life-threatening diseases.
- "Receiving this orphan designation in the European Union is an important regulatory milestone for Mersana as we seek to expedite UpRi’s global development," MRSN CEO Anna Protopapas said in a statement .
- MRSN stock closed +4.2% at $7.03 on Tuesday.
For further details see:
Mersana Therapeutics gets European orphan drug designation for ovarian cancer treatment